Sapient Partners with Rancho BioSciences to Accelerate the Next Generation of its Human Biology Database

October 24, 2024—San Diego, CA—Sapient, a leading biomarker discovery organization providing at scale services for multi-omics data generation and analysis, has announced a collaboration with Rancho Biosciences, a best-in-class provider of tech enabled life science data science services, to accelerate the next generation of the Sapient Human Biology Database. This in-house database is already comprised of metabolomic, lipidomic, proteomic, and genomic measures collected in more than 100,000 human biosamples, alongside more than 130 million paired phenotypic data points, which Sapient utilizes in its clients’ projects to validate and mine for biomarkers, identify drug targets, and derive biological insights to inform drug development decisions. Building upon this foundation, Rancho will support an infrastructure expansion to both accelerate the ingestion of additional multi-omics and real-world data and to homogenize new and existing datasets, further increasing the breadth and depth of multidimensional insights that can be delivered.

“We believe strongly that integrated multi-omics data will play a critical role in the future of drug development, revealing how varied molecular interactions influence disease to enable better subtyping and drug targeting,” said Tao Long, Co-Founder and Head of Data Science at Sapient. “We’re investing in this future by working with Rancho on the next generation of our database. We’re creating a pathway to efficiently add more types of omics data, including more proteomics and genomics measures, alongside patient data that is standardized and curated for discovery. Ultimately this will increase the speed, versatility, and depth of our analyses – and the power of the data insights we can deliver to clients.”

Rancho will deploy subject matter experts (SMEs) versed in the curation of diverse internal and public life science datasets, including from clinical trials, patient health records, and genomics, to support the project. “We are excited to partner with Sapient and build upon the high-quality data assets they have assembled,” said Julie Bryant, Founder and CEO of Rancho BioSciences. “Rancho’s subject matter expertise and strategic use of AI will accelerate growth of the Human Biology Database, increasing the velocity and impact of Sapient’s data analyses. Rancho continues to set the standard for multi-omics data integration that delivers tangible value to drug development through tech enablement and high quality data.” 

“We selected Rancho as our partner of choice not only because we found them to be best-in-class in terms of their data engineering capabilities, but also for their deep expertise in clinical data ontology,” said Jamie Cho, Head of Software Engineering at Sapient. “Their understanding of real-world data architectures, combined with our expertise handling different types of omics data, is a perfect pairing to enable the next evolution of our database and support the future of insight delivery for our customers.”

###

About Sapient

Sapient is a leading biomarker discovery organization providing bespoke, at scale multi-omics services for proteomics, metabolomics, and lipidomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development. Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers in human, preclinical, and cellular biosamples, across thousands of samples at a time.

These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data; robust quality control analysis; and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using our proprietary in-house Human Biology Database that includes data from over 100,000 human biosamples with paired phenotypic measures. Together our approaches enable rapid identification of drug targets and discovery, validation, and translation of dynamic biomarkers of biological processes, disease mechanisms, and drug response across all drug development phases. For more information, visit sapient.bio.

About Rancho BioSciences

Rancho BioSciences is a Data Science Services company headquartered in San Diego, California. With subject matter expertise in data curation, data analysis, AI, LLM and machine learning, Rancho BioSciences empowers organizations in the life sciences and healthcare sectors to derive meaningful insights from complex data, ultimately accelerating research and discovery. For more information, visit ranchobiosciences.com.

Media Contact:
Carla Nieser
Head of Marketing, Sapient
carla.nieser@sapient.bio
858.290.7010